Puma BiotechnologyPBYI
About: Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Employees: 185
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
191% more call options, than puts
Call options by funds: $166K | Put options by funds: $57K
43% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 23
1% more funds holding
Funds holding: 99 [Q2] → 100 (+1) [Q3]
6% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 18
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
4.25% less ownership
Funds ownership: 64.89% [Q2] → 60.63% (-4.25%) [Q3]
26% less capital invested
Capital invested by funds: $102M [Q2] → $75.8M (-$26.2M) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Edward White 22% 1-year accuracy 19 / 86 met price target | 124%upside $7 | Buy Reiterated | 20 Nov 2024 |
HC Wainwright & Co. Edward White 22% 1-year accuracy 19 / 86 met price target | 124%upside $7 | Buy Reiterated | 8 Nov 2024 |
Financial journalist opinion
Based on 9 articles about PBYI published over the past 30 days
